Mitsubishi Chemical says it would dissolve Quebec’s Medicago because it is no longer ‘viable’ to continue marketing its products
The Quebec-based biopharmaceutical firm that produced a COVID-19 vaccine is being shut down by parent company Mitsubishi Chemical.
Mitsubishi Chemical said it had been preparing to commercially produce the Covifenz vaccine but decided against doing so because of the “significant changes” in theThe company said it would dissolve Medicago because it is no longer “viable” to continue marketing its products.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Medicago to cease operations in Quebec, scuttling COVID-19 vaccine production plans | Globalnews.caMedicago has shut down its COVID-19 vaccine project in Quebec after its sole shareholder decided to no longer invest in the company, the company announced Thursday.
Read more »
Quebec-based COVID-19 vaccine maker Medicago to shut down | CBC NewsMedicago owner Mitsubishi Chemical Group said on Thursday that it was terminating 'all its activities with Medicago,' citing 'significant changes' to the vaccine market.
Read more »
COVID-19 update: Quebec reports eight more deathsThe province\u0027s death toll since the start of the pandemic now stands at 17,962.
Read more »
COVID-19 Kraken subvariant continues to spread in QuebecOfficially known as XBB.1.5, it\u0027s the only variant whose spread is growing significantly, Quebec\u0027s public health institute said Wednesday.
Read more »
Nemaska Lithium buys Quebec land, eyes Canada’s 1st processing plantNemaska Lithium has purchased a site and begun clearing land in Bécancour, Que., for construction of what could become Canada’s first processing plant capable of producing battery-grade lithium for electric vehicles.
Read more »
Quebec discussions with electric battery makers at ‘advanced’ stage“It’s premature to make an announcement but I’m very optimistic,” says Investissement Québec chief executive Guy LeBlanc.
Read more »